KIN

Kindred Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.035
-0.005
-0.12%
Opening 13:27 08/13 EDT
OPEN
4.020
PREV CLOSE
4.040
HIGH
4.120
LOW
4.020
VOLUME
93.33K
TURNOVER
--
52 WEEK HIGH
11.93
52 WEEK LOW
3.105
MARKET CAP
158.85M
P/E (TTM)
-5.1924
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average KIN stock price target is 11.64 with a high estimate of 14.00 and a low estimate of 9.00.

EPS

KIN News

More
Kindred Biosciences, Inc.'s (KIN) CEO Richard Chin on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 5d ago
Kindred Biosciences (KIN) Q2 Earnings and Revenues Beat Estimates
Kindred Bio (KIN) delivered earnings and revenue surprises of 333.33% and 100.19%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/05 22:25
Kindred Biosciences (KIN) Reports Next Week: Wall Street Expects Earnings Growth
Kindred Bio (KIN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/29 16:33
Kindred Biosciences to Announce Second Quarter 2020 Financial Results
Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, will release its second quarter 2020 financial results on August 5, 2020, after the market close. The Company will host a conference call at
PR Newswire · 07/23 12:32
Is Vaxart Stock a Buy?
MotleyFool.com · 07/09 12:06
Kindred Bio (KIN) Upgraded to Buy: Here's Why
Zacks · 07/08 17:00
Is the Options Market Predicting a Spike in Kindred Biosciences (KIN) Stock?
Zacks · 06/29 13:51
Better Coronavirus Stock: VBI Vaccines or Vaxart?
MotleyFool.com · 06/27 12:12

Industry

Biotechnology & Medical Research
+0.56%
Pharmaceuticals & Medical Research
-1.22%

Hot Stocks

Symbol
Price
%Change

About KIN

Kindred Biosciences, Inc. is a development-stage biopharmaceutical company. The Company is focused on developing therapies for pets. The Company's product pipeline consists of small molecules and biologics for a range of indications in dogs, cats and horses. The Company is developing product candidates for over 20 indications and focused on small molecule products and canine and feline biologics products. The Company is developing antibodies that targets canine Interleukin 17A (IL-17a), Interleukin 4A (IL-4Ra), Interleukin 3 (IL-3), CD-20, Immunoglobulin E (IgE), tumor necrosis factors (TNF) and other validated targets. The Company's lead product candidates are Zimeta, which is indicated for the treatment of fever in horses, and KIND-010 for management of weight loss in cats. The Company's other product candidates include KIND-010, KIND-014, KIND-015, KIND-510, KIND-502, KIND-0888, KIND-509, and several antibodies that target cytokines involved in atopic dermatitis.
More

Webull offers kinds of Kindred Biosciences Inc stock information, including NASDAQ:KIN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KIN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KIN stock methods without spending real money on the virtual paper trading platform.